KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Work In Process (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Work In Process for 13 consecutive years, with $29.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Work In Process rose 10.14% to $29.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $29.4 million, a 10.14% increase, with the full-year FY2025 number at $29.4 million, up 10.14% from a year prior.
  • Work In Process was $29.4 million for Q4 2025 at Supernus Pharmaceuticals, down from $33.4 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $46.2 million in Q1 2022 to a low of $9.3 million in Q1 2021.
  • A 5-year average of $28.1 million and a median of $27.5 million in 2023 define the central range for Work In Process.
  • Peak YoY movement for Work In Process: soared 408.75% in 2021, then tumbled 36.0% in 2023.
  • Supernus Pharmaceuticals' Work In Process stood at $45.7 million in 2021, then crashed by 30.63% to $31.7 million in 2022, then decreased by 1.57% to $31.2 million in 2023, then decreased by 14.38% to $26.7 million in 2024, then increased by 10.14% to $29.4 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Work In Process are $29.4 million (Q4 2025), $33.4 million (Q3 2025), and $15.6 million (Q2 2025).